In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Study reveals worrying decline in medication use after heart surgery

SWEDEHEART trial presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Cardiovascular Surgery
CV Surgery - Coronary Arteries

Paris, France – 3 Sept 2019: Use of preventive medications is high early after heart surgery but decreases significantly over time, according to late breaking results from the SWEDEHEART registry presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology (1). This is despite the fact that many of these drugs are linked with lower mortality.

First author Dr Erik Bjoerklund of Sahlgrenska Academy, Gothenburg, Sweden said: “The study shows that continuous treatment with statins, RAAS inhibitors, and platelet inhibitors is essential for long-term survival after coronary artery bypass grafting (CABG). The observed decrease in use of these medications over time after CABG is therefore alarming and poses an area for improvement.”

CABG is the preferred method of revascularisation in patients with complex multivessel coronary artery disease. It is estimated that 200,000 procedures are performed in the US each year and the incidence in Europe is on average 44 per 100,000 per year. In 2018 in Sweden 2,473 isolated CABG procedures were registered in SWEDEHEART.

Since the indication for CABG is complex coronary artery disease (three-vessel disease or left main stenosis, especially for diabetic patients) it is considered high-risk for future events. European guidelines recommend statins and platelet inhibitors for all CABG patients without contraindications; RAAS inhibitors for those with left ventricular ejection fraction (LVEF) below 40%, hypertension or previous myocardial infarction; and (long-term) beta-blockers for patients with LVEF below 40% or previous myocardial infarction. (2)

Limited published data suggest that use of prevention medication after CABG is surprisingly low and markedly lower compared to patients treated with percutaneous coronary intervention. Furthermore, the associations between use of these therapies and mortality risk in a real-world setting has been poorly described.

This study examined the use of prevention medications (statins, beta-blockers, RAAS inhibitors, and platelet inhibitors) after CABG over time and the association with mortality.

The analysis included all 28,812 patients who underwent isolated first-time CABG in Sweden in 2006 to 2015 and were alive six months after hospital discharge. The Swedish personal identification number was used to merge data from several mandatory nationwide registries including the Swedish Cardiac Surgery registry which is a part of SWEDEHEART. Data on mortality and dispensed prescriptions (recorded every three months) were collected until the end of 2015. Patients were followed-up for a median of five years.

The use of prevention medication was high early after surgery but decreased significantly over time. Statins were dispensed to 93.9% of patients six months after discharge from surgery and 77.3% eight years later. Corresponding figures for beta-blockers were 91.0% and 76.4%; RAAS inhibitors 72.9% and 65.9%; and platelet inhibitors 93.0% and 79.8%.

Dr Bjoerklund noted that the study did not distinguish between legitimate reasons for not using the drugs (i.e. contraindications), doctors’ non-prescription, and patient non-adherence. But he said: “One reason behind the fall in medications over time could be that in Sweden many CABG patients are not routinely seen by cardiologists beyond six to 12 months after the operation. Another factor may be that CABG relieves symptoms, so patients feel healthy and their motivation to use multiple daily medications wanes over the years.”  

There were no major differences in the use of medications between women and men. However, all of the drugs were dispensed less often to patients aged 75 and older. Dr Bjoerklund said patients over 75 may have contraindications or there might be less focus on improving their long-term survival compared to younger patients. But he added: “The survival benefits we observed were across ages, so our study does not support treating patients over 75 differently to younger patients.”

After adjusting for age, sex, comorbidities, and use of other prevention medications, statins, RAAS inhibitors and platelet inhibitors were significantly associated with 44%, 22%, and 26% lower relative risks of mortality, respectively. No association was found between use of beta-blockers and risk of mortality.

Total time using statins, RAAS inhibitors, and platelet inhibitors (but not beta-blockers) was significantly associated with lower mortality risk. Each additional year using statins, platelet inhibitors, and RAAS inhibitors was linked with 10%, 7%, and 2% lower relative risks of mortality, respectively. “This indicates that continuous treatment with these medications is important for long-term survival,” said Dr Bjoerklund.

Regarding the lack of mortality benefit with beta-blockers, Dr Bjoerklund pointed out that the only randomised study published on routine use of beta-blockers after CABG did not find any difference in mortality. (3) He said: “It is somewhat surprising that we did not even find an association between use of beta-blockers and mortality risk in the subset of patients with reduced LVEF. However, our data on LVEF was recorded as above or below 50% and it is possible that more specific information might have revealed an association. The role of long-term treatment with beta-blockers to improve survival after CABG needs to be further investigated.”


Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding: The study was supported by the Swedish Heart-Lung Foundation (grant no. 20170459 to Anders Jeppsson), the Swedish state (grant 20150587 to AJ) under the agreement between the Swedish government and the county councils concerning economic support of research and education of doctors (ALF agreement), and Västra Götaland Region (grant no. 847811 to AJ). The supporting bodies had no influence on the analysis and interpretation of data, on the writing of the report, or on the decision to submit the paper for publication.

Disclosures: Anders Jeppsson has received research grants, speaker’s honorarium, and consultancy honorarium from AstraZeneca and speaker’s and consultancy honorarium from Boehringer-Ingelheim. Emma C Hansson has received speaker’s honorarium from AstraZeneca and Boehringer-Ingelheim. Carl Johan Malm has received speaker’s honorarium from AstraZeneca. None of the other co-authors have any conflicts of interests.

References and notes

(1) SWEDEHEART will be discussed during:

(2) Sousa-Uva M, Head SJ, Milojevic M, et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2018;53:5–33. doi:10.1093/ejcts/ezx314.

(3) Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. Eur Heart J. 1995;16:1825–1832.

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.